Innovation Pharmaceuticals Inc (IPIX)

[Blue Fin]

I found Today's Zach Hartman's analysis was totally misleading and very irresponsible, Here is the post in its entirety, pisses me off:

"Innovation trying to live up to its name in ovarian cancer
Company: Innovation Pharmaceuticals (OTCQB:IPIX)
Therapy: Kevetrin
Disease: Ovarian cancer
News: IPIX (formerly Cellceutix) announced that, upon observation supporting the successful activation of p53, they will be closing a phase 2a study investigating their developmental drug Kevetrin, which was being given in intravenous formulation. Now, the company will focus on developing an oral formulation that they'll attempt to move through the clinic.

Looking forward: Likely this is a move that could pay off well for IPIX in the future. However, right now it looks like they're shuttering a promising clinical program just as they're demonstrating proof of concept. They must be confident in their ability to move an oral formulation through phase 2 faster than they might be able to get their IV formulation through phase 3 and to approval. There's also the added risk now of an oral formulation not working the same way. So overall this seems like an odd move on their part.
I would hold off on making a big investment decision based on this news alone, but if they have a bona fide p53 activator, it could be a very big deal in cancer medicine. But it is worth considering that IPIX has had a very bumpy history of failure in drug development, and the large losses and this negative history should definitely be a part of the calculation. I highly recommend taking in a more thorough long and short take on IPIX".